Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Davis UCLA
Dates
study started
completion around
Principal Investigator
by John M Timmerman, MD (ucla)

Description

Summary

This phase II trial studies how well anakinra works in preventing severe chimeric antigen receptor T-cell-related encephalopathy syndrome after chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma that has come back or has not responded to treatment. Immunosuppressive therapy, such as anakinra, is used to decrease the body?s immune response, which may prevent severe chimeric antigen receptor T-cell-related encephalopathy syndrome.

Official Title

IL-1 Receptor Antagonist to Prevent Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome

Details

Keywords

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Progressive Disease, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Lymphoma, Follicular Lymphoma, B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Brain Diseases, Recurrence, Disease Progression, Vidarabine, Cyclophosphamide, Fludarabine, Fludarabine phosphate, Axicabtagene ciloleucel, Interleukin 1 Receptor Antagonist Protein, Anakinra, Prevention (anakinra, CAR T-cell therapy)

Eligibility

Locations

  • UC Davis Comprehensive Cancer Center accepting new patients
    Davis California 95817 United States
  • UCLA / Jonsson Comprehensive Cancer Center accepting new patients
    Los Angeles California 90095 United States

Lead Scientist at University of California Health

  • John M Timmerman, MD (ucla)
    Professor, Medicine. Authored (or co-authored) 75 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Jonsson Comprehensive Cancer Center
ID
NCT04205838
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 36 study participants
Last Updated